Brief: Valbiotis Targets Own Marketing Of Its Products In France

Valbiotis SA

07/10/2022 06:41

Oct 7 (Reuters) - VALBIOTIS SA  ALVAL.PA :
    * VALBIOTIS ACCELERATES ITS MARKETING STRATEGY
    * STRATEGY: FIRSTLY, SIGNING OF INTERNATIONAL PARTNERSHIPS
(GLOBAL
OR REGIONAL) WITH MAJOR PLAYERS IN NUTRITION AND HEALTHCARE
SECTORS
    * STRATEGY: SECONDLY, COMPANY'S OWN MARKETING OF ITS
PRODUCTS ON
FRENCH MARKET
    * DUAL STRATEGY WILL ENABLE IT TO RAPIDLY TARGET GLOBAL FOOD
SUPPLEMENT MARKET, ESTIMATED AT 250 BILLION EUROS IN 2025, WITH
ANNUAL GROWTH OF 9.6%, INCLUDING 3.2 BILLION EUROS FOR FRANCE
    * ENTERING A NEW PHASE OF ITS DEVELOPMENT FOCUSED ON REVENUE
GENERATION AND STRUCTURING COMPANY TO GIVE THIS PRODUCT
PORTFOLIO EVERY CHANCE OF SUCCESS ON A GLOBAL SCALE
    * SEARCH FOR INTERNATIONAL LICENSING OR DISTRIBUTION
AGREEMENTS
FOR TOTUM•070, TOTUM•448 AND TOTUM•854 WITH MAJOR NUTRITION AND
HEALTH PLAYERS
    * DIRECT MARKETING IN FRANCE OF TOTUM•070, TOTUM•448 AND
TOTUM•854
WILL ENSURE THAT VALBIOTIS CAN RAPIDLY AND INDEPENDENTLY DEVELOP
ITS TURNOVER
    * WILL CONTINUE ITS STRUCTURING TO SECURE SUPPLY CHAIN FOR
FUTURE
COMMERCIALIZATIONS, AND WILL MAINTAIN ITS RESEARCH EFFORTS TO
PREPARE TOMORROW'S PIPELINE
    * AMBITION IS TO FINALIZE SIGNATURE OF INTERNATIONAL
LICENSING OR
DISTRIBUTION AGREEMENTS FOR TOTUM•070 BY SECOND HALF OF 2023
    * VALBIOTIS' AMBITION IS TO FINALIZE SIGNATURE OF
INTERNATIONAL
LICENSING OR DISTRIBUTION AGREEMENTS FOR TOTUM•070 BY SECOND
HALF OF 2023
    * TOTUM•070, WHOSE PHASE II CLINICAL STUDY WAS HIGHLY
SUCCESSFUL,
WILL BE FIRST PRODUCT MARKETED BY VALBIOTIS IN FRANCE. IT IS
SCHEDULED TO BE LAUNCHED IN H1 2024, FOLLOWED BY TOTUM•448 AND
TOTUM•854 IN 2024-2025
    * EXECUTION OF STRATEGY WILL BE FINANCED BY VALBIOTIS' CASH
FLOW
AND EXPECTED REVENUES FROM PARTNERSHIP WITH NESTLÉ HEALTH
SCIENCE (WHICH HAS ALREADY GENERATED 8 MLN EUROS IN CASH SINCE
ITS SIGNATURE)
    * EXECUTION OF STRATEGY IS ALSO CONDITIONAL ON OBTAINING
ADDITIONAL FINANCING, TERMS OF WHICH ARE CURRENTLY BEING STUDIED

Source text for Eikon:  ID:nBw8MXx3a 
Further company coverage:  ALVAL.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))